Inhibition of dynamin by dynole 34-2 induces cell death following cytokinesis failure in cancer cells

Molecular Cancer Therapeutics

Volumn 10, Issue 9, 2011, Pages 1553-1562

  Chircop, Megan ^a   Perera, Swetha ^a   Mariana, Anna ^a   Lau, Hui ^d   Ma, Maggie P C ^a   Gilbert, Jayne ^b   Jones, Nigel C ^d   Gordon, Christopher P ^c   Young, Kelly A ^c   Morokoff, Andrew ^d   Sakoff, Jennette ^b   O'Brien, Terence J ^d   McCluskey, Adam ^c   Robinson, Phillip J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CALCINEURIN; DYNAMIN; DYNOLE 25; DYNOLE 26; DYNOLE 33; DYNOLE 34 2; DYNOLE 35; ENZYME INHIBITOR; GAMMA TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; COLON CANCER; CYTOKINESIS; DNA FRAGMENTATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER;

ACRYLAMIDES; ANIMALS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCINEURIN; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; CYTOKINESIS; DYNAMINS; FIBROBLASTS; HELA CELLS; HT29 CELLS; HUMANS; INDOLES; MICE; NEOPLASMS; POLYPLOIDY; PROTEIN KINASE INHIBITORS; QUINOLINES; THIAZOLES; TUBULIN;

EID: 80052710376     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0067     Document Type: Article

References (38)

1. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17. (Pubitemid 46160987)
2. Taylor S, Peters JM. Polo and Aurora kinases-lessons derived from chemical biology. Curr Opin Cell Biol 2008;20:77-84.
3. Joshi S, Perera S, Gilbert J, Smith CM, Gordon CP, McCluskey A, et al. The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells. Mol Cancer Ther 2010;9:1995-2006.
4. Hill TA, Odell LR, Quan A, Abagyan R, Ferguson G, Robinson PJ, et al. Long chain amines and long chain ammonium salts as novel inhibitors of dynamin GTPase activity. Bioorg Med Chem Letts 2004;14:3275-8. (Pubitemid 38624606)
5. Quan A, McGeachie AB, Keating DJ, Van Dam EM, Rusak J, Chau N, et al. Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin II. Mol Pharmacol 2007;72:1425-39. (Pubitemid 350146080)
6. Praefcke GJK, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol 2004;5:133-47. (Pubitemid 38160256)
7. Hinshaw JE. Dynamin and its role in membrane fission. Annu Rev Cell Dev Biol 2000;16:483-519. (Pubitemid 32037515)
8. Sever S, Damke H, Schmid SL. Dynamin:GTP controls the formation of constricted coated pits, the rate limiting step in clathrin-mediated endocytosis. J Cell Biol 2000;150:1137-48.
9. Newton AJ, Kirchhausen T, Murthy VN. Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc Natl Acad Sci U S A 2006;103:17955-60. (Pubitemid 44852267)
10. Chircop M, Malladi CS, Lian AT, Page SL, Zavortink M, Gordon CP, et al. Calcineurin activity is required for the completion of cytokinesis. Cell Mol Life Sci 2010;67:3725-37.
11. Feng B, Schwarz H, Jesuthasan S. Furrow-specific endocytosis during cytokinesis of zebrafish blastomeres. Exp Cell Res 2002;279:14-20.
12. Liu YW, Surka MC, Schroeter T, Lukiyanchuk V, Schmid SL. Isoform and splice-variant specific functions of dynamin-2 revealed by analysis of conditional knock-out cells. Mol Biol Cell 2008;19:5347-59.
13. Thompson HM, Skop AR, McNiven MA. Dynamin is a component of the intercellular bridge and is required for cytokinesis in hepatocytes. Hepatol 2002;36:212A.
14. Thompson HM, Skop AR, Euteneuer U, Meyer BJ, McNiven MA. The large GTPase dynamin associates with the spindle midzone and is required for cytokinesis. Curr Biol 2002;12:2111-7. (Pubitemid 36021888)
15. Hill T, Odell LR, Edwards JK, Graham ME, McGeachie AB, Rusak J, et al. Small molecule inhibitors of dynamin I GTPase activity: development of dimeric tyrphostins. J Med Chem 2005;48:7781-8. (Pubitemid 41698817)
16. Hill TA, Gordon CP, McGeachie AB, Venn-Brown B, Odell LR, Chau N, et al. Inhibition of dynamin mediated endocytosis by the dynoles™-synthesis and functional activity of a family of indoles. J Med Chem 2009;52:3762-73.
17. Hill TA, Mariana A, Gordon CP, Odell LR, Robertson MJ, McGeachie AB, et al. Iminochromene inhibitors of dynamins I and II GTPase activity and endocytosis. J Med Chem 2010;53:4094-102.
18. Odell LR, Howan D, Gordon CP, Robertson MJ, Chau N, Mariana A, et al. The pthaladyns: GTP competitive inhibitors of dynamin I and II GTPase derived from virtual screening. J Med Chem 2010;53:5267-80.
19. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 2006;10:839-50. (Pubitemid 43779110)
20. Vassilev LT, Tovar C, Chen SQ, Knezevic D, Zhao XL, Sun HM, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A 2006;103:10660-5. (Pubitemid 44078033)
21. Chircop M, Oakes V, Graham ME, Ma MP, Smith CM, Robinson PJ, et al. The actin-binding and bundling protein, EPLIN, is required for cytokinesis. Cell Cycle 2009;8:757-64.
22. Chircop M, Sarcevic B, Larsen MR, Malladi CS, Chau N, Zavortink M, et al. Phosphorylation of dynamin II at serine-764 is associated with cytokinesis. Biochim Biophys Acta Epub 2010 Dec 29.
23. Orth JD, Tang Y, Shi J, Loy CT, Amendt C, Wilm C, et al. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther 2008;7:3480-9.
24. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-70.
25. Huszar D, Theoclitou ME, Skolnik J, Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 2009;28:197-208.
26. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104:4106-11. (Pubitemid 47181586)
27. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8. (Pubitemid 46955132)
28. Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007;6:3147-57.
29. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-80. (Pubitemid 36529846)
30. Dreier MR, Grabovich AZ, Katusin JD, Taylor WR. Short and long-term tumor cell responses to Aurora kinase inhibitors. Exp Cell Res 2009;315:1085-99.
31. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12. (Pubitemid 40991810)
32. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-22.
33. Bekier ME, Fischbach R, Lee J, Taylor WR. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol Cancer Ther 2009;8:1646-54.
34. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 2001;12:1315-28. (Pubitemid 33044413)
35. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-77. (Pubitemid 44289225)
36. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 2008;112:2886-95.
37. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-10.
38. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32.